Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinic…
Biotechnology
US, San Diego [HQ]
MRTX/Leadership and Strategy
Risk Factors
Annual
Not Available
No Risk Factor available yet. You can request "Risk Factors" through an email.
Quarter
Not Available